Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity
暂无分享,去创建一个
R. Pounder | J. Sercombe | M. Hudson | S. Lim | A. Sawyerr | S. Lim | Mark Hudson | A. Sawyerr | S. G. Lim
[1] J. L. Goodman,et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.
[2] J. Lesher. NEW ANTIFUNGAL AGENTS , 1992, Dermatologic clinics.
[3] M. Diaz,et al. Itraconazole in the treatment of coccidioidomycosis. , 1991, Chest.
[4] D. Denning,et al. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. , 1991, Chest.
[5] J. Morrow. Fluconazole: a new triazole antifungal agent. , 1991, The American journal of the medical sciences.
[6] W. Hendriks,et al. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. , 1991, The Netherlands journal of medicine.
[7] C. Shikuma,et al. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. , 1991, Journal of the American Academy of Dermatology.
[8] F. Barchiesi,et al. Fluconazole, itraconazole and ketoconazole in-vitro activity. A comparative study. , 1991, Journal of chemotherapy.
[9] Jerome J. Schentag,et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. , 1991, Annals of Internal Medicine.
[10] M. Winter,et al. Fluconazole for oropharyngeal candidiasis in anti‐HIV positive haemophiliacs , 1991, Alimentary pharmacology & therapeutics.
[11] S. F. Kowalsky,et al. Fluconazole: a new antifungal agent. , 1991, Clinical pharmacy.
[12] R. Powles,et al. The prophylaxis of fungal infections. , 1991, The Journal of antimicrobial chemotherapy.
[13] R. Hay. Antifungal therapy and the new azole compounds. , 1991, The Journal of antimicrobial chemotherapy.
[14] J. Thorpe,et al. Effect of Oral Antacid Administration on the Pharmacokinetics of Oral Fluconazole , 1990, Antimicrobial Agents and Chemotherapy.
[15] G. Cauwenbergh,et al. Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review. , 1990, British journal of clinical practice. Supplement.
[16] S. Piscitelli,et al. Fluconazole: A New Triazole Antifungal Agent , 1990, DICP : the annals of pharmacotherapy.
[17] N. Blatchford. Treatment of oral candidosis with itraconazole: a review. , 1990, Journal of the American Academy of Dermatology.
[18] J. Galgiani. Fluconazole, a new antifungal agent. , 1990, Annals of internal medicine.
[19] S. Mühldorfer,et al. Prophylaxis of fungal infections with itraconazole in immunocompromised cancer patients , 1990, Mycoses.
[20] A. Brown. Overview of fungal infections in cancer patients. , 1990, Seminars in oncology.
[21] J. D. Lazar,et al. The clinical pharmacology of fluconazole. , 1990, Seminars in oncology.
[22] E. Bailey,et al. The Triazole Antifungal Agents: A Review of Itraconazole and Fluconazole , 1990, Pharmacotherapy.
[23] P. Robinson,et al. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. , 1990, Reviews of infectious diseases.
[24] J. Fay,et al. High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. , 1990, Seminars in oncology.
[25] C. Nord,et al. Oral yeast infections in immunocompromised and seriously diseased patients. , 1990, Acta odontologica Scandinavica.
[26] K. Brammer. Management of fungal infection in neutropenic patients with fluconazole. , 1990, Haematology and blood transfusion.
[27] R. Pounder,et al. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. , 1990, Alimentary pharmacology & therapeutics.
[28] G. Sarosi. Amphotericin B. Still the 'gold standard' for antifungal therapy. , 1990, Postgraduate medicine.
[29] P. Vanparys,et al. Toxicological Profile and Safety Evaluation of Antifungal Azole Derivatives , 1989, Mycoses.
[30] R. Woestenborghs,et al. The Clinical Pharmacokinetics of Itraconazole: An Overview , 1989, Mycoses.
[31] S. Clissold,et al. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. , 1989, Drugs.
[32] P. Cohen,et al. Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.
[33] E. Straus,et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). , 1988, Annals of internal medicine.
[34] R. Pounder,et al. The effects of famotidine, 40 mg at night, on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. , 1988, Scandinavian journal of gastroenterology.
[35] J. Barone,et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. , 1988, Clinical pharmacy.
[36] D. Warnock,et al. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. , 1988, The Journal of antimicrobial chemotherapy.
[37] S. D. Roberts,et al. Behçet's disease presenting as benign intracranial hypertension. , 1986, Postgraduate medical journal.
[38] R. Pounder,et al. Effect of oral famotidine on 24-hour intragastric acidity. , 1986, Postgraduate medical journal.
[39] H. Mann,et al. Effect of pH on disintegration and dissolution of ketoconazole tablets. , 1983, American journal of hospital pharmacy.
[40] J. V. D. van der Meer,et al. The influence of gastric acidity on the bio-availability of ketoconazole. , 1980, The Journal of antimicrobial chemotherapy.
[41] F. Odds,et al. Candida and candidosis , 1979 .